Immunocore’s (IMCR) Buy Rating Reiterated at HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $100.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 203.03% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. Needham & Company LLC restated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Friday, January 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, UBS Group began coverage on Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Stock Up 0.9 %

Immunocore stock opened at $33.00 on Monday. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a 1-year low of $27.69 and a 1-year high of $76.98. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -34.74 and a beta of 0.76. The firm’s fifty day moving average price is $30.53 and its two-hundred day moving average price is $33.33.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. During the same period in the previous year, the company posted ($0.59) EPS. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. On average, equities research analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently modified their holdings of IMCR. Exchange Traded Concepts LLC boosted its holdings in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares during the period. Connective Portfolio Management LLC bought a new position in shares of Immunocore in the third quarter worth $218,000. China Universal Asset Management Co. Ltd. grew its position in shares of Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after purchasing an additional 3,053 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Immunocore during the 3rd quarter valued at $406,000. Finally, Alpha DNA Investment Management LLC purchased a new stake in Immunocore during the 3rd quarter worth about $411,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.